HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Open Access
- 31 October 2023
- journal article
- research article
- Published by Universitas Airlangga in (JOINTS) Journal Orthopaedi and Traumatology Surabaya
- Vol. 12 (2) , 49-58
Abstract
Background: Zoledronic acid as bisphosphonates could increase bone mineral density (BMD), which in osteogenesis imperfecta will reduce clinical manifestations. Pediatric patients with osteogenesis imperfecta given zoledronic acid therapy should improve their quality of life. Methods: A retrospective analytic study was conducted on 16 pediatric osteogenesis imperfecta patients who had received intravenous zoledronic acid. Interview using PedsQL 4.0 regarding the condition before and after therapy assessed the quality of life. A paired t-test was used to assess the contrast in each aspect of PedsQL 4.0. Results were expressed as an adjusted odds ratio with a 95% confidence interval. P-value Results: A significant increase was found in the child report of social performance (+12.083, p=0.023), and proxy report of physical performance, social performance, and total score of the proxy report (+14.844, p=0.006; +10.625, p=0.010; +10.364, p=0.006). An insignificant increase was found in the child report of physical performance, school performance, and total score of the child report (+8.833, p=0.148; +5.000, p=0.359; +7.065, p=0.115), and proxy report of emotional performance and school performance (+2.500, p=0.669; +6.250, p=0.167). An insignificant decrease was found in child reports of emotional performance (-2.500, p=0.669). Conclusion: After receiving bisphosphonate therapy, pediatric patients with osteogenesis imperfecta experienced an increased quality of life in most aspects within every perception. Physical and social aspects experienced the greatest improvement. Emotional is the aspect that experienced the lowest increase in the child's perception and decreased parent perception of the value of quality of life after bisphosphonate therapy.Keywords
This publication has 20 references indexed in Scilit:
- Reliability and validity of the PedsQL 4.0 Generic Core Scales in pediatric vision impairmentJournal of American Association for Pediatric Ophthalmology and Strabismus, 2020
- Health-related quality of life in children with osteogenesis imperfecta: a large-sample studyOsteoporosis International, 2018
- Osteogenesis imperfecta – A clinical updateMetabolism, 2018
- Bisphosphonate therapy for osteogenesis imperfectaCochrane Database of Systematic Reviews, 2016
- Quality of life in osteogenesis imperfecta: A mixed‐methods systematic reviewAmerican Journal of Medical Genetics Part A, 2015
- Mechanical and mineral properties of osteogenesis imperfecta human bones at the tissue levelBone, 2014
- Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCTJournal of Bone and Mineral Research, 2012
- Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trialEuropean Journal of Pediatrics, 2007
- Osteogenesis imperfecta in childhood: Impairment and disability. a prospective study with 4-year follow-up11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the author(s) or on any organization with which the author(s) is/are associated.Archives of Physical Medicine and Rehabilitation, 2004
- Quality of life in osteogenesis imperfectaInternational Orthopaedics, 2001